Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PTC Therapeutics and Cystic Fibrosis Foundation Therapeutics, the non-profit affiliate of the Cystic Fibrosis Foundation, have expanded an existing collaboration to support development of PTC124, the PTC's new investigational oral drug for the treatment of cystic fibrosis caused by nonsense mutations.
Subscribe to our email newsletter
PTC will receive up to $25 million from Cystic Fibrosis Foundation Therapeutics in support of key Phase IIb clinical trials for PTC124 in cystic fibrosis (CF).
Stuart Peltz, president and CEO of PTC Therapeutics, said: “We look forward to initiating registration-directed studies of PTC124 for nonsense-mutation- mediated CF within the next few months.”